Celemics signs an agreement to supply BTSeq™ to Sangon Biotech Co., Ltd., a Chinese genetic analysis company

Celemics signs a supply agreement for BTSeq™ solution with Chinese Sanger sequencing service company

Celemics, South Dakota State University, announce partnership for the development of Hybridization NGS-based Multiple Swine Pathogen Co-Detection Panel

Celemics, Strand Life Sciences Partner on Integrated Platform for NGS Analysis

Celemics: Not All NGS Companies Are the Same
Contact Us
SEARCH
COUNTRY / REGION
BTSeq™ Service Order
Contact Sales
  • Just like a chameleon utilizing its
    colored pigments and crystals to
    adapt to its surroundings,
    we proactively pioneer and adapt to
    the everchanging NGS markets with
    our cutting-edge technology to
    support our customer’s needs.
ONLINE ORDER

BRCA 1/2 Sequencing Service

Comprehensive and Accurate Analysis of BRCA 1/2 Genes

Qualified with Clinical Grade Performance

Overview

Celemics’ BRCA 1/2 Target Enrichment Sequencing Service is
designed to enrich whole coding sequences (CDS) of the BRCA1
and BRCA2 genes including UTR, promoter, and +/- 40 bases
of CDS to detect the variants in the splicing site.

Using the Celemics’ BRCA 1/2 Panel, customers can obtain information on all types
of variants including large indel and CNV. High performance of the panel guarantees reliable and consistent sequencing results
to customers even if using DNA from low-quality clinical samples or FFPE. Additionally, Celemics provides clinical grade report from our proprietary
bioinformatics pipeline with Strand LifeScience.
이미지

Features &
Benefits

  • 이미지
    Targets the whole CDS (+/- 40) and promoter regions of
    BRCA 1/2 with high specificity
    Target regions not only covering the CDS regions but expanded to
    +40 and -40 of CDS to detect the splicing site variants
    Probes specifically designed for detecting deletion, duplication,
    and large rearrangement
  • 이미지
    Compatible with a variety of sample types
    No compromise on panel performance regardless of using DNA
    from challenging Specimen types such as blood and FFPE
  • 이미지
    Market leading panel performance in uniformity and coverage
    Designed to target the whole exon regions of BRCA 1, 2 gene with 100%
    coverage (RefSeq) and validated to yield 100% coverage
  • 이미지
    Clinical grade performance
    The CE-IVD obtained target enrichment panel
    Upper than 95% of sensitivity and 99.5% of specificity
    of all types of mutations (SNV and Indel)
  • 이미지
    Provision of Bioinformatics SW
    FASTQ to annotated VCF
    Clinical grade report
    EU-GDPR compliant through usage of Europe-based server

Performance

Market leading panel performance in Uniformity and Coverage Comparison data with competitors' products

  • 이미지
  • 이미지
  • The extremely low standard deviation of uniformity enables consistent and reliable sequencing results
  • In-house test of the panel shows 100% of coverage for all target regions including whole CDS (+/- 40 bp), UTR, and promoter region

User-friendly analysis report with information of all types of variants and CNV

이미지
  • The extremely low standard deviation of uniformity enables consistent and reliable sequencing results
  • In-house test of the panel shows 100% of coverage for all target regions including whole CDS (+/- 40 bp), UTR, and promoter region

Applications

  • 이미지

    Breast and Ovarian cancer related fields

Resources